Early Treatment of the Common Cold with Intranasal Interferon Alpha-2a (Ro 22–8181): A Preliminary Pilot Study
- 43 Downloads
It is well established that intranasal IFN Alpha-2a is effective in preventing experimental and natural rhinovirus-induced common cold (1–3). Seven-day contact prophylaxis is well tolerated and approximately 80% of rhinovirus respiratory virus infections are prevented (4, 5). There is little information about therapeutic effect of intranasal interferon in symptomatic patients. Hayden and Gwaltney (6) found only modest effects on nasal symptoms in experimentally induced rhinovirus infection when treatment was initiated 28 hours after the virus inoculation.
KeywordsRespiratory Syncytial Virus Acute Respiratory Tract Infection Respiratory Syncytial Virus Infection Common Cold Total Symptom Score
- 2.Herzog C, Berger R, Fernex M, Friesecke K, Haval L, Just M, Dubach UC, Havas L, Just M and Dubach U: Intranasal interferon (rIFN-alpha A, Ro 22–8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study. Antiviral Research 1986; 6: 171–176.PubMedCrossRefGoogle Scholar
- 3.Intranasal interferon alpha-2 prophylaxis of natural respiratory virus infection. The Journal of Infectious Diseases 1985; 151, No. 46.Google Scholar
- 7.Hennes U, Jucker W, Fischer EA, Krummenacher T, Palleroni AV, Trown PW, Linder-Ciccolunghi S and Rainisio M: Detection of antibodies to recombinant interferon alpha 2a in human serum: Evaluation of three methods. Submitted to J. of Biological Standardization.Google Scholar
- 8.Halonen P and Meurman O (1982): Radioimmunoassay in diagnostic virology. In: New developments in practical virology. Ed. Howard CR (Alan R. Liss, New York ), pp 83–124.Google Scholar